Get started
Author

Patrick Simon Zbyszewski

Observed names: P. Zbyszewski, P.S. Zbyszewski, Patrick S Zbyszewski, Patrick S. Zbyszewski
OpenAlex ID: A5020992385
A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia
2017 · Shyamala C. Navada, Steven M. Fruchtman, et al. · Leukemia Research · 44
Analysis of professional competencies for the clinical research data management profession: implications for training and professional certification
2017 · Meredith N Zozus, Angel Lazarov, et al. · Journal of the American Medical Informatics Association · 26
PDF
Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study
2020 · Shyamala C. Navada, Guillermo Garcia-Manero, et al. · Leukemia Research · 21
Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS)
2019 · Guillermo Garcia-Manero, Shyamala C. Navada, et al. · Blood · 17
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care
2017 · Aziz Nazha, Mikkael A. Sekeres, et al. · Blood Cancer Journal · 16
PDF
Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients
2018 · Shyamala C. Navada, Guillermo Garcia-Manero, et al. · Blood · 14
Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
2019 · Shyamala C. Navada, Guillermo Garcia-Manero, et al. · Blood · 11
Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study
2016 · Shyamala C. Navada, Guillermo Garcia-Manero, et al. · Blood · 4
Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
2016 · Guillermo Garcia-Manero, Pierre Fenaux, et al. · Blood · 4
Evaluation of Underlying Cause of Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes upon Oral Administration of Rigosertib: Safety and Pharmacokinetic Analysis of Rigosertib across Three Clinical Trials
2018 · Manoj Maniar, Chen Ren, et al. · Blood · 3
Mutational Landscape of MDS Patients with HMA Failure Revealed By the Correlative Analysis from Inspire Trial
2021 · Koichi Takahashi, Anna Jonasova, et al. · Blood · 1
Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)
2019 · Guillermo Garcia-Manero, Anna Jonasova, et al. · Blood · 1
S839 Phase Ii Study of Oral Rigosertib Combined With Azacitidine in Patients With Higher‐risk Myelodysplastic Syndromes (mds)
2019 · S.C. Navada, G. Garcia‐Manero, et al. · HemaSphere · 1
Amelioration of Rigosertib Treatment Related Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes: Implementation of Novel Dosing Regimen Derived through Pharmacokinetic Modeling in Phase 2 Study of Oral Rigosertib in Combination with Azacitidine
2018 · David Taft, Tarang Vora, et al. · Blood · 1
Relationship of bone marrow blast (BMBL) response to overall survival (OS) in a multicenter study of rigosertib (Rigo) in patients (pts) with myelodysplastic syndrome (MDS) with excess blasts progressing on or after treatment with a hypomethylating agent (HMA).
2017 · Aref Al-Kali, Devendra Hiwase, et al. · Journal of Clinical Oncology · 1
Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS)
2017 · S. Navada, G. Garcia-Manero, et al. · Leukemia Research
A Validation of a Post-Hypomethylating Agent Failure (HMAF) Prognostic Model in MDS Patients Treated with Rigosertib Versus Best Supportive Care (BSC)
2017 · A. Nazha, M. Sekeres, et al. · Leukemia Research
A Genomic Predictive Signature for Rigosertib in Lower Risk MDS Derived By Integrating Clinical Response, Mechanism of Action Data and Simulation
2016 · Steven M. Fruchtman, Abdullah Mahmood Ali, et al. · Blood
Works count: 18
Citation count: 165
H-index: 7
I10-index: 7
Year
Topic
Type